Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2024-03-28 Regulatory Filings
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-03-28 English
FWP
Capital/Financing Update Classification · 100% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433, which is a SEC rule related to prospectus supplements and securities offerings. It discusses details of a public offering of common stock and pre-funded warrants, including offering size, use of proceeds, dilution, and risk factors. The content is focused on capital raising activities and securities issuance. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is a detailed offering prospectus supplement, which fits the category of Capital/Financing Update (CAP).
2024-03-27 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of common stock, including the number of shares, underwriting discounts, use of proceeds, risk factors, and other offering-related information. The document is clearly related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of financial report. The presence of underwriting details and offering terms indicates this is a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but a substantive prospectus supplement.
2024-03-26 English
10-K
Annual Report FY 2023
2024-03-25 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 25, 2024. It announces the issuance of a press release and an investor presentation regarding new clinical data. The document explicitly states that the press release and presentation are furnished as exhibits and incorporated by reference, and that the information is not deemed "filed" for certain regulatory purposes. The document itself is relatively short (3767 characters) and primarily serves to announce and furnish other materials rather than containing substantive financial data or detailed report content. The presence of an investor presentation as an exhibit suggests the main content is investor-focused presentation material. Given these factors, the document is best classified as an Investor Presentation (IP) filing type, as it includes and references a presentation with detailed information for investors. The Form 8-K is a regulatory filing vehicle, but the content focus here is on the presentation and press release announcement. Confidence is high due to clear identification of the presentation and the nature of the filing.
2024-03-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 25, 2024, reporting the issuance of a press release announcing full year 2023 financial results. The text states that the press release is attached as an exhibit and does not contain the financial results itself. The document length is 3056 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for such filings that announce or attach other documents but do not contain substantive financial data themselves.
2024-03-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.